Cyclohexanone oxime

Dermal absorption

Administrative data

Endpoint:

dermal absorption in vivo

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1991

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Acceptable, well-documented publication

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Data source

Reference

Reference Type:

publication

Title:

Unnamed

Year:

1991

Report date:

1991

Materials and methods

Principles of method if other than guideline:

toxicokinetic study, no guideline available

GLP compliance:

not specified

Test material

Test material information

Constituent 1

Reference substance name:

Cyclohexanone oxime

EC Number:

202-874-0

EC Name:

Cyclohexanone oxime

Cas Number:

100-64-1

Molecular formula:

C6H11NO

IUPAC Name:

cyclohexanone oxime

Test material form:

not specified

Details on test material:

Name of test material (as cited in study report): cyclohexanone oxime
- Analytical purity: unlabelled material from supplier recrystallised

Radiolabelling:

yes

Remarks:

[1-C14]-cyclohexanone oxime, specific activity 6.85 mCi per mmol

Test animals

Species:

rat

Strain:

Fischer 344

Sex:

male

Administration / exposure

Type of coverage:

semiocclusive

Vehicle:

acetone

Duration of exposure:

24 h

Doses:

30 mg/kg bw

No. of animals per group:

3

Control animals:

no

Details on study design:

Dermal exposure: The interscapular region was clipped 24 h before exposure. The animals were anesthesised with ketamine and 30 mg/kg bw were applied at 0.2 mL/kg bw in a circular area of 1 cm2. The application site was covered with a perforated metal tissue capsule, glued directly to the skin. The aminals were kept individually in metabolism cages and sacrificed 24 h after exposure.

Results and discussion

Signs and symptoms of toxicity:

not specified

Dermal irritation:

not specified

Absorption in different matrices:

- Skin test site: 4.52 % of adminstered dose remaining after 24 h
- Blood: 0.053 %
- Carcass: tissues: 0.408 %; liver: 0.036 %; kidney: 0.007 %; skin: 0.099 %; muscle: 0.036 %; small intestine: 0.007 %; small intestine content: 0.026 %; large intestine: 0.006 %; large intestine content: 0.046 %
- Urine: 3.86 %
- Faeces: 0.089 %
- Volatiles: 22.6 %

Total recovery:

- Total recovery: 31.4 %

Percutaneous absorption

Dose:

30 mg/kg bw

Parameter:

percentage

Absorption:

ca. 5 %

Remarks on result:

other: 24 h

Any other information on results incl. tables

Distribution and elimination after dermal application were not different from those observed after oral administration.

Applicant's summary and conclusion

Conclusions:

Under the conditions of this study the systemic absorption after dermal expposure was approx. 5%

Executive summary:

Three male rats were exposed dermally to 30 mg/kg bw. Within 24 h after exposure start, 3.9% was excreted in urine and 0.1% in feces, 4.5% remained at the application site and 23% had volatilised within 3 -5 min after application. Therefore the systemic uptake after dermal exposure is in the range of 5% of the administered dose.